Overcoming Resistance: Virologic Response to a Salvage Regimen with the Combination of Ritonavir plus Indinavir

REFERENCES

• Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Eng J Med. 1998;338:853–860
   PubMed Web of Science ®Google Scholar
• Casado JL, Perez-Elias MJ, Antela A, et al. Predictors of long-term response to protease inhibitor therapy in a co-hort of HIV-infected patients. AIDS. 1998;12:F131–135.
   PubMed Web of Science ®Google Scholar
• d'Arminio Monforte A, Cozzi Lepri A, Rezza G, et al. In-sights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients. AIDS. 2000;14:499-507.
   PubMed Web of Science ®Google Scholar
• Hirsch MS, Conway B, D'Aquila RT, et al. Antiretroviral drug resistance testing in adults with HIV infection: implica-tions for clinical management. JAMA. 1998;279:1984–1991.
   PubMed Web of Science ®Google Scholar
• Molla A, Korneyeva M, Gao Q, et al. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat Med. 1996;2:760–766.
   PubMed Web of Science ®Google Scholar
• Baxter JD, Mayers DL, Wentworth DN, et al. A randomized study of antiretroviral management based on plasma geno-typic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Com-munity Programs for Clinical Research on AIDS. AIDS. 2000;14:F83–F93.
   PubMed Web of Science ®Google Scholar
• Durant J, Clevenberg P, Halfon P, et al. Drug resistance genotyping in HIV-1 therapy: the VIRADAPT randomized controlled trial. Lancet. 1999;353:2195–2199.
   PubMed Web of Science ®Google Scholar
• Schmidt B, Walter H, Moschik B, et al. Simple algorithm derived from a geno-/phenotypic database to predict HIV-1 protease inhibitor resistance. AIDS. 2000;14:1731–1738.
   PubMed Web of Science ®Google Scholar
• Rice H, Zolopa A, Shulman N, Condra J. Determination of clinically relevant phenotypic resistance breakpoints for indinavir/ritonavir containing antiretroviral regimens. In: Program and abstracts of the Fifth International Workshop on HIV Drug Resistance and Treatment Strategies; June 4–8, 2001; Scottsdale, Arizona. Abstract 41.
   Google Scholar
• Condra JH, Petropoulos CJ, Ziermann R, et al. Drug resis-tance and predicted virologic responses to human immu-nodeficiency virus type 1 protease inhibitor therapy. J In-fect Dis. 2000;182:758–765.
   PubMed Web of Science ®Google Scholar
• van Heeswijk RP, Veldkamp Al, Hoetelmans RM, et al. The steady-state plasma pharmacokinetics of indinavir alone and in combination with a low dose of ritonavir in twice daily dosing regimens in HIV-1 infected individuals. AIDS. 1999;13:F90–F99.
   Web of Science ®Google Scholar
• Kempf D, Marsh KC, Kumar G, et al. Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Antimicrob Agents Chemother. 1997;41:654–660.
   PubMed Web of Science ®Google Scholar
• van Praag RME, Weverling GJ, Portergies P, et al. En-hanced penetration of indinavir in cerebrospinal fluid and semen after the addition of low-dose ritonavir. AIDS. 2000;14:1187–1194.
   PubMed Web of Science ®Google Scholar
• Rockstroh JK, Bergmann F, Wiesel W, et al. Efficacy and safety of twice daily first-line ritonavir/indinavir plus double nucleoside combination therapy in HIV-infected individu-als. AIDS. 2000;14:1181–1185.
   PubMed Web of Science ®Google Scholar
• Durant J, Clevenbergh P, Garraffo R, et al. Importance of protease inhibitor plasma levels in HIV infected patients treated with genotypic guided therapy: pharmacological data from the Viradapt study. AIDS. 2000;14:1333–1339.
   PubMed Web of Science ®Google Scholar
• Burger DM, Hoetelmans RM, Hugen PW, et al. Low plasma concentrations of indinavir are related to virologic treat-ment failure in HIV-1 infected patients on indinavir contain-ing triple therapy. Antivir Ther. 1998;3:215–220.
   PubMed Web of Science ®Google Scholar
• Casado JL, Moreno A, Sabido R, et al. A clinical study of the combination of 100 mg ritonavir plus 800 mg indinavir as salvage therapy: influence of increased plasma drug levels in the rate of response. HIV Clin Trials. 2000;1(1):13–19.
   PubMedGoogle Scholar
• Kawle SP, Remmel RP, Weller OD, Fletcher CV. A simulta-neous HPLC assay for quantification of indinavir, saquinavir, ritonavir, and nelfinavir in human plasma. In: Program and abstracts of the Fifth Conference on Retroviruses and Opportunistic Infections; 1998; Chicago, Illinois.
   Google Scholar
• Carpenter CC, Cooper DA, Fischl MA, et al. Antiretroviral therapy in adults: updated recommendations of the Inter-national AIDS Society-USA Panel. JAMA. 2000;283:381–390.
   PubMed Web of Science ®Google Scholar
• The EuroGuidelines Group for HIV Resistance. Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommenda-tions for the European setting. AIDS. 200115: 309–320.
   Google Scholar
• Dieleman JP, Gyssens IC, van der Ende M, de Marie S, Burger DM. Urological complaints in relation to indinavir plasma concentrations in HIV-infected patients. AIDS. 1999;13:473–478.
   PubMed Web of Science ®Google Scholar
• Gatell JM, Lange J, Arnaiz JA, et al. A randomized study comparing continued indinavir (800 mg tid) to indinavir/ ritonavir (800/100 mg bid) in HIV patients having achieved viral load with indinavir plus two nucleosides analogues: the BID efficacy and safety trial (BEST). In: Program and abstracts of the XIII International AIDS Conference; July 9–14, 2000; Durban. Abstract WeOrB484.
   Google Scholar